Seagen cordially invites you to learn more about TUKYSA
Objective: Review data rom HER2CLIMB, a global, randomized, double-blind, controlled trial evaluating TUKYSA vs placebo, each in combination with trastuzumab + capecitabine
SPEAKER: Dr. Carol Tweed
Maryland Oncology Hematology
Annapolis, MD
DATE AND TIME: November 14, 2023
Tuesday at 6:00 pm
LOCATION: Mon Ami Gabi
7239 Woodmont Avenue, Bethesda, MD 20814
RSVP: Lindsay Paik
lpaik@seagen.com, 301-613-5579